Top

Published in:

01-04-2013 | Article

Cardiotrophin 1 protects beta cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model

Authors: M. Jiménez-González, F. Jaques, S. Rodríguez, A. Porciuncula, R. M. Principe, G. Abizanda, M. Iñiguez, J. Escalada, J. Salvador, F. Prósper, P. A. Halban, M. Barajas

Published in: Diabetologia | Issue 4/2013

Abstract

Aims/hypothesis

Cardiotrophin 1 (CT-1) is a recently described cytokine originally isolated from the heart where it has been shown to play an important role in apoptotic protection of cardiomyocytes and heart hypertrophy. Its beneficial properties have also been described in other organs such as liver and neuromuscular tissue. In the present study, we investigated whether CT-1 can confer protection against pro-apoptotic stimuli in pancreatic beta cells, and its role in insulin secretion and diabetes development.

Methods

The effects of CT-1 on apoptosis and function were studied using MIN6B1 cells and freshly isolated murine pancreatic islets. The impact on the development of diabetes was evaluated in Ct1-null (Ct1 ^−/−) mice (the gene Ct1 is also known as Ctf1) using two streptozotocin (STZ)-induced models of diabetes.

Results

CT-1 has a protective effect in MIN6B1 cells and murine islets under the pro-apoptotic stimulus of serum deprivation, which correlates with the expression of B cell lymphoma-extra large, or following exposure to a mixture of cytokines. In addition, CT-1 enhances glucose-stimulated insulin secretion in MIN6B1 cells and this was repressed by inhibitors of phospholipase C. Furthermore, Ct1 ^−/− mice were more prone to develop diabetes, and their glucose tolerance test showed impaired plasma glucose clearance which correlated with decreased pancreatic insulin secretion.

Conclusions/interpretation

The results obtained from both in vitro and in vivo experiments show that CT-1 improves beta cell function and survival, and protects mice against STZ-induced diabetes.

Available only for authorised users

American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69CrossRef

Maedler K, Sergeev P, Ehses JA et al (2004) Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 101:8138–8143PubMedCrossRef

Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA (2011) Bimodal effect on pancreatic beta-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60:1111–1121PubMedCrossRef

Pennica D, King KL, Shaw KJ et al (1995) Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A 92:1142–1146PubMedCrossRef

Robledo O, Fourcin M, Chevalier S et al (1997) Signaling of the cardiotrophin-1 receptor. Evidence for a third receptor component. J Biol Chem 272:4855–4863PubMedCrossRef

Mitsumoto H, Klinkosz B, Pioro EP et al (2001) Effects of cardiotrophin-1 (CT-1) in a mouse motor neuron disease. Muscle Nerve 24:769–777PubMedCrossRef

Bustos M, Beraza N, Lasarte JJ et al (2003) Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. Gastroenterology 125:192–201PubMedCrossRef

Iñíguez M, Berasain C, Martinez-Anso E et al (2006) Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med 203:2809–2815PubMedCrossRef

Choi SE, Choi KM, Yoon IH et al (2004) IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol 13:43–53PubMedCrossRef

10.

Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489PubMedCrossRef

11.

Wallenius V, Wallenius K, Ahrén B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79PubMedCrossRef

12.

Deutsch G, Jung J, Zheng M, Lora J, Zaret KS (2001) A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 128:871–881PubMed

13.

Zaret KS, Watts J, Xu J, Wandzioch E, Smale ST, Sekiya T (2008) Pioneer factors, genetic competence, and inductive signaling: programming liver and pancreas progenitors from the endoderm. Cold Spring Harb Symp Quant Biol 73:119–126PubMedCrossRef

14.

Lilla V, Webb G, Rickenbach K et al (2003) Differential gene expression in well-regulated and dysregulated pancreatic beta-cell (MIN6) sublines. Endocrinology 144:1368–1379PubMedCrossRef

15.

Oppenheim RW, Wiese S, Prevette D et al (2001) Cardiotrophin-1, a muscle-derived cytokine, is required for the survival of subpopulations of developing motoneurons. J Neurosci 21:1283–1291PubMed

16.

Li DS, Yuan YH, Tu HJ, Liang QL, Dai LJ (2009) A protocol for islet isolation from mouse pancreas. Nat Protoc 4:1649–1652PubMedCrossRef

17.

Yermen B, Tomas A, Halban PA (2007) Pro-survival role of gelsolin in mouse beta-cells. Diabetes 56:80–87PubMedCrossRef

18.

Kannan Y, Tokunaga M, Moriyama M, Kinoshita H, Nakamura Y (2004) Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice. Clin Exp Immunol 137:263–271PubMedCrossRef

19.

Negoro S, Kunisada K, Tone E et al (2000) Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47:797–805PubMedCrossRef

20.

Railson JE, Liao Z, Brar BK et al (2002) Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine 17:243–253PubMedCrossRef

21.

Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR (1997) Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 272:5783–5791PubMedCrossRef

22.

Lee YH, Bae SS, Seo JK, Choi I, Ryu SH, Suh PG (2000) Interleukin-6-induced tyrosine phosphorylation of phospholipase C-gamma1 in PC12 cells. Mol Cells 10:469–474PubMed

23.

Park KH, Na K, Jung SY, Kim SW, Cha KY, Chung HM (2005) Insulinoma cell line (MIN6) adhesion and spreading mediated by Arg-Gly-Asp (RGD) sequence conjugated in thermo-reversible gel. J Biosci Bioeng 99:598–602PubMedCrossRef

24.

Shimizu H, Ohtani K, Kato Y, Mori M (2000) Interleukin-6 increases insulin secretion and preproinsulin mRNA expression via Ca2+-dependent mechanism. J Endocrinol 166:121–126PubMedCrossRef

25.

Suzuki T, Imai J, Yamada T et al (2011) Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway. Diabetes 60:537–547PubMedCrossRef

26.

Zawalich WS, Zawalich KC (1996) Regulation of insulin secretion by phospholipase C. Am J Physiol 271:E409–E416PubMed

27.

Jaques F, Jousset H, Tomas A et al (2008) Dual effect of cell-cell contact disruption on cytosolic calcium and insulin secretion. Endocrinology 149:2494–2505PubMedCrossRef

28.

Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297–314PubMed

29.

Schwarze MM, Hawley RG (1995) Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 55:2262–2265PubMed

30.

Peters A (2010) Incretin-based therapies: review of current clinical trial data. Am J Med 123(3 Suppl):S28–S37PubMedCrossRef

31.

Yamazaki H, Zawalich KC, Zawalich WS (2010) Physiologic implications of phosphoinositides and phospholipase C in the regulation of insulin secretion. J Nutr Sci Vitaminol (Tokyo) 56:1–8CrossRef

32.

Bonal C, Avril I, Herrera PL (2008) Experimental models of beta-cell regeneration. Biochem Soc Trans 36:286–289PubMedCrossRef

33.

Amirshahrokhi K, Dehpour AR, Hadjati J, Sotoudeh M, Ghazi-Khansari M (2008) Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice. Toxicol Appl Pharmacol 232:119–124PubMedCrossRef

34.

Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356PubMedCrossRef

35.

Natal C, Fortuno MA, Restituto P et al (2008) Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab 294:E52–E60PubMedCrossRef

36.

Zvonic S, Hogan JC, Arbour-Reily P, Mynatt RL, Stephens JM (2004) Effects of cardiotrophin on adipocytes. J Biol Chem 279:47572–47579PubMedCrossRef

37.

Moreno-Aliaga MJ, Perez-Echarri N, Marcos-Gomez B et al (2011) Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab 14:242–253PubMedCrossRef

38.

Robador PA, Moreno MU, Beloqui O et al (2010) Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. J Hypertens 28:2219–2226PubMedCrossRef

39.

Erdmann J, Hassfeld S, Kallisch H, Fleck E, Regitz-Zagrose V (2000) Genetic variants in the promoter (g983G>T) and coding region (A92T) of the human cardiotrophin-1 gene (CTF1) in patients with dilated cardiomyopathy. Hum Mutat 16:448PubMedCrossRef

Title: Cardiotrophin 1 protects beta cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model
Authors: M. Jiménez-González
F. Jaques
S. Rodríguez
A. Porciuncula
R. M. Principe
G. Abizanda
M. Iñiguez
J. Escalada
J. Salvador
F. Prósper
P. A. Halban
M. Barajas
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 4/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2822-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiotrophin 1 protects beta cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 4/2013

Metformin and mortality

Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects

List of Referees

1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus

Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3

Growth arrest specific protein (GAS) 6: a role in the regulation of proliferation and functional capacity of the perinatal rat beta cell

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page